| Q2 2024 |
66 |
$405M |
+$158M |
-$74.2M |
+$84.1M |
MRUS, NUVL, RNA, URGN, ERAS
|
13F-HR |
8/14/2024, 01:44 PM |
| Q1 2024 |
73 |
$357M |
+$116M |
-$143M |
-$27M |
MRUS, SLDB, MORF, ORIC, MRSN
|
13F-HR |
5/14/2024, 05:37 PM |
| Q4 2023 |
64 |
$324M |
+$138M |
-$129M |
+$9.53M |
MRUS, MRSN, MORF, NUVL, PSTX
|
13F-HR |
2/14/2024, 10:28 AM |
| Q3 2023 |
68 |
$268M |
+$92.2M |
-$88.1M |
+$4.07M |
IMGN, MORF, MRUS, SLNO, ITCI
|
13F-HR |
11/13/2023, 09:29 AM |
| Q2 2023 |
77 |
$296M |
+$111M |
-$56.1M |
+$55.4M |
IMGN, MRUS, MORF, SDGR, KRYS
|
13F-HR |
8/14/2023, 09:53 AM |
| Q1 2023 |
67 |
$223M |
+$83M |
-$125M |
-$41.8M |
MRUS, MGNX, VRAYQ, PSTX, ORIC
|
13F-HR |
5/15/2023, 09:57 AM |
| Q4 2022 |
81 |
$290M |
+$97.5M |
-$66.2M |
+$31.3M |
MDGL, BLU, PSTX, VRAYQ, XENE
|
13F-HR |
2/14/2023, 12:29 PM |
| Q3 2022 |
69 |
$236M |
+$76M |
-$65.1M |
+$10.9M |
BLU, VCYT, AKRO, MORF, COGT
|
13F-HR |
10/28/2022, 05:06 PM |
| Q2 2022 |
59 |
$213M |
+$71.9M |
-$47.6M |
+$24.4M |
ITCI, BLU, VCYT, CERS, MRUS
|
13F-HR |
7/25/2022, 03:27 PM |
| Q1 2022 |
55 |
$175M |
+$46.1M |
-$41.8M |
+$4.37M |
ITCI, SRRA, VCYT, CTIC, MRUS
|
13F-HR |
5/13/2022, 04:32 PM |
| Q4 2021 |
68 |
$223M |
+$83.7M |
-$34.3M |
+$49.5M |
IMGN, BHVNXXXX, ITCI, MRUS, VCYT
|
13F-HR |
2/14/2022, 09:12 AM |
| Q3 2021 |
78 |
$173M |
+$46.5M |
-$60.1M |
-$13.6M |
BHVNXXXX, VCYT, MRTX, MRUS, AMYT
|
13F-HR |
11/15/2021, 03:01 PM |
| Q2 2021 |
87 |
$187M |
+$75.4M |
-$60.7M |
+$14.7M |
DRNA, MRUS, MRTX, VCYT, MORF
|
13F-HR |
8/16/2021, 03:24 PM |
| Q1 2021 |
88 |
$178M |
+$63.8M |
-$55M |
+$8.85M |
ACRS, CRIS, VCEL, INSM, AMYT
|
13F-HR |
5/17/2021, 06:02 PM |
| Q4 2020 |
80 |
$164M |
$0 |
$0 |
|
VCEL, ITCI, DCTH, INSM, AMYT
|
13F-HR |
2/16/2021, 05:09 PM |